| Pair Name | Gallic acid, Doxorubicin | ||
| Phytochemical Name | Gallic acid (PubChem CID: 370 ) | ||
| Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Gallic acid, Doxorubicin | |||
| Disease Info | [ICD-11: 2B33.4] | Leukemia | Investigative | |
| Gene Regulation | Down-regulation | Expression | ABCB1 | hsa5243 |
| In Vitro Model | K-562 | Blast phase chronic myelogenous leukemia | Homo sapiens (Human) | CVCL_0004 |
| Result | GA enhanced the anticancer effect of Pira on K562 and K562/Dox cancer cells through cellular energy status impairment, and was able to reverse drug resistance in living K562/Dox cancer cells by inhibiting the function of P‑glycoprotein. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Gallic acid enhances pirarubicin‑induced anticancer in living K562 and K562/Dox leukemia cancer cells through cellular energetic state impairment and P‑glycoprotein inhibition. Oncol Rep. 2021 Oct;46(4):227. doi: 10.3892/or.2021.8178. | Click |
